Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Guralp Onur Ceyhan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3626-7423; OpenAlex author ID A5007646286, A5024023211. Sources: OpenAlex.

Their work

Papers
55 (first author 1, last author 16)
Trials
0
Grants
0
Labs led
2
Collaborators
193
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: 1 paper · 2015: 3 papers · 2016: 1 paper · 2017: 5 papers · 2018: 8 papers · 2019: 4 papers · 2020: 8 papers · 2021: 3 papers · 2022: 4 papers · 2023: 2 papers · 2024: 5 papers · 2025: 5 papers · 2026: 3 papers

Papers 50 of 55

  1. Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Last author DOI 10.1007/s00423-026-04291-0↗
  2. Heterogeneity in the management of patients with locally advanced pancreatic cancer: current surgeons' perspective and lessons for the future. Co-author DOI 10.1007/s13304-026-02651-5↗
  3. Pancreatic ductal adenocarcinoma: The Vision of Heracles. Co-author DOI 10.1016/j.ccell.2026.07.014↗
  4. Pancreatic cancer cells survive in the neural niche during neoadjuvant therapy. Co-author DOI 10.1016/j.canlet.2025.217894↗
  5. Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. Co-author DOI 10.1016/j.ccell.2025.09.003↗
  6. Pancreatic cancer cells infiltrate nerves through TGFbeta1-driven perineural epithelial-to-mesenchymal-like transdifferentiation. Co-author DOI 10.1016/j.neo.2025.101126↗
  7. Neural invasion severity is a strong predictor of local recurrence in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.surg.2024.109018↗
  8. TRANSCRIPTOMIC ANALYSIS OF THE RELATIONSHIP BETWEEN PANCREATIC DUCTAL ADENOCARCINOMA STROMAL SUBTYPES AND NEURAL INVASION Last author DOI 10.1101/2025.01.13.632859↗
  9. Dynamics and cytokinic regulation of immune cell infiltration in genetically engineered mouse models of pancreatic cancer dictate the sensitivity to immunother… Co-author DOI 10.1002/cac2.12496↗
  10. A retrospective, multicentric, nationwide analysis of the impact of splenectomy on survival of pancreatic cancer patients. Co-author DOI 10.1007/s00423-024-03570-y↗
  11. Correlation of intratumoral mast cell quantity with psychosocial distress in patients with pancreatic cancer: the PancStress study. Co-author DOI 10.1038/s41598-024-77010-8↗
  12. Lymph node examination and survival in resected pancreatic ductal adenocarcinoma: retrospective study. Co-author DOI 10.1093/bjsopen/zrad125↗
  13. Margin clearance greater than 1 mm in nodal-positive pancreatic adenocarcinoma patients: multicentre retrospective analysis. Co-author DOI 10.1093/bjsopen/zrae076↗
  14. Arterial Resection for Pancreatic Cancer: Feasibility and Current Standing in a High-Volume Center. Co-author DOI 10.1097/as9.0000000000000302↗
  15. Phenotype screens of murine pancreatic cancer identify a Tgf-α-Ccl2-paxillin axis driving human-like neural invasion. Co-author DOI 10.1172/jci166333↗
  16. Venous resection for pancreatic cancer, a safe and feasible option? A systematic review and meta-analysis. Last author DOI 10.1016/j.pan.2022.05.001↗
  17. Molecular Profiling in Pancreatic Cancer: Current Role and Its Impact on Primary Surgery. Co-author DOI 10.1159/000519755↗
  18. The Effect of Celiac Neurolysis and Splanchnicectomy on Survival in Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.1159/000520456↗
  19. Genetic landscape of pancreatic cancer: a narrative review. Last author DOI 10.21037/cco-22-4↗
  20. Innervated mouse pancreas organoids as an ex vivo model to study pancreatic neuropathy in pancreatic cancer. Co-author DOI 10.1016/j.xpro.2021.100935↗
  21. Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. Co-author DOI 10.1053/j.gastro.2021.03.051↗
  22. Patterns and Relevance of Langerhans Islet Invasion in Pancreatic Cancer. Co-author DOI 10.3390/cancers13020249↗
  23. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  24. The quality of pain management in pancreatic cancer: A prospective multi-center study. Co-author DOI 10.1016/j.pan.2020.08.017↗
  25. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is f… Co-author DOI 10.1016/j.suronc.2020.08.031↗
  26. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells. Co-author DOI 10.1158/1078-0432.ccr-19-1864↗
  27. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Co-author DOI 10.1172/jci.insight.137809↗
  28. In the Era of the Leeds Protocol: A Systematic Review and A Meta-Analysis on the Effect of Resection Margins on Survival Among Pancreatic Ductal Adenocarcinoma… Co-author DOI 10.1177/1457496920911807↗
  29. Indirect cholinergic activation slows down pancreatic cancer growth and tumor-associated inflammation. Co-author DOI 10.1186/s13046-020-01796-4↗
  30. Mechanisms of T-Cell Exhaustion in Pancreatic Cancer. Co-author DOI 10.3390/cancers12082274↗
  31. Perineural invasion in pancreatic cancer: proteomic analysis and in vitro modelling. Co-author DOI 10.1002/1878-0261.12463↗
  32. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection. Co-author DOI 10.1016/j.suronc.2019.08.010↗
  33. Borderline-resectable pancreatic adenocarcinoma: Contour irregularity of the venous confluence in pre-operative computed tomography predicts histopathological … Co-author DOI 10.1371/journal.pone.0208717↗
  34. Venous resection during pancreatectomy for pancreatic cancer: a systematic review. Last author DOI 10.21037/tgh.2019.06.01↗
  35. Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/bjs5.46↗
  36. Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jcmgh.2018.07.003↗
  37. Pain in pancreatic ductal adenocarcinoma: A multidisciplinary, International guideline for optimized management. Co-author DOI 10.1016/j.pan.2018.04.008↗
  38. MTOR inhibitor-based combination therapies for pancreatic cancer. Co-author DOI 10.1038/bjc.2017.421↗
  39. R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000002345↗
  40. Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-17-2415↗
  41. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-17-2180↗
  42. Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer. Co-author DOI 10.1186/s12943-018-0806-0↗
  43. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Last author DOI 10.1016/j.ctrv.2017.03.003↗
  44. pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2017.06.034↗
  45. The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Last author DOI 10.1016/j.suronc.2017.01.007↗
  46. Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cells. Last author DOI 10.1073/pnas.1606909114↗
  47. Epigenomic therapies: the potential of targeting SIRT6 for the treatment of pancreatic cancer. First author DOI 10.1080/14728222.2017.1265507↗
  48. Activated Schwann cells in pancreatic cancer are linked to analgesia via suppression of spinal astroglia and microglia. Last author DOI 10.1136/gutjnl-2015-309784↗
  49. Neural plasticity in pancreatitis and pancreatic cancer. Last author DOI 10.1038/nrgastro.2015.166↗
  50. Back pain as a potential indicator of local recurrence in pancreatic cancer. Last author DOI 10.1093/jscr/rjv127↗

Closest collaborators

The 25 strongest of 193 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. İhsan Ekin Demir · 38 shared papers, 2011–2026 · strength 4.77
  2. Helmut Friess · 20 shared papers, 2011–2026 · strength 2.71
  3. Carmen Mota Reyes · 14 shared papers, 2017–2026 · strength 2.00
  4. Helmut Frieß · 19 shared papers, 2013–2025 · strength 1.84
  5. Stephan Schorn · 16 shared papers, 2013–2025 · strength 1.67
  6. Okan Safak · 10 shared papers, 2020–2025 · strength 1.59
  7. Ilaria Pergolini · 7 shared papers, 2022–2026 · strength 1.36
  8. Rüdiger Göß · 8 shared papers, 2017–2025 · strength 1.29
  9. Alexander Muckenhuber · 9 shared papers, 2017–2025 · strength 1.10
  10. Hana Algül · 10 shared papers, 2013–2026 · strength 1.01
  11. Dieter Saur · 6 shared papers, 2018–2026 · strength 0.82
  12. Alexander Novotny · 4 shared papers, 2023–2026 · strength 0.80
  13. Kıvanç Görgülü · 5 shared papers, 2021–2026 · strength 0.73
  14. Linhan Ye · 5 shared papers, 2021–2025 · strength 0.72
  15. Benediktas Kurlinkus · 4 shared papers, 2020–2026 · strength 0.72
  16. Asif Halimi · 4 shared papers, 2020–2026 · strength 0.72
  17. Eline S. Zwart · 4 shared papers, 2020–2026 · strength 0.72
  18. Johanna Laukkarinen · 4 shared papers, 2020–2026 · strength 0.72
  19. Reea Ahola · 4 shared papers, 2020–2026 · strength 0.72
  20. Marc Eric Martignoni · 4 shared papers, 2020–2026 · strength 0.69
  21. Lei Ren · 5 shared papers, 2020–2025 · strength 0.65
  22. Roland Rad · 5 shared papers, 2018–2026 · strength 0.61
  23. Saliha Elif Yıldızhan · 3 shared papers, 2023–2025 · strength 0.58
  24. Patrick Maisonneuve · 4 shared papers, 2020–2026 · strength 0.58
  25. Mert Erkan · 4 shared papers, 2011–2026 · strength 0.55

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.